Trioxaquines: hybrid molecules for the treatment of malaria.
Drug News Perspect
; 23(10): 632-46, 2010 Dec.
Article
in En
| MEDLINE
| ID: mdl-21180649
Artemisinin, with its 1,2,4-trioxane as active motif, is now the first-line treatment for multidrug-resistant malaria. The endoperoxide ring is essential for the antimalarial activity of artemisinin. Based on its mechanism of action, new hybrid molecules named trioxaquines with a dual mode of action have been designed. Trioxaquines are made by the covalent attachment of a trioxane, having alkylating ability, to a quinoline, known to easily penetrate within infected erythrocytes. This review discusses the importance of various hybrid molecules of artemisinin and 4-aminoquinoline in the treatment of malaria and the evolution of a trioxaquine hybrid as a promising antimalarial drug candidate.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Artemisinins
/
Malaria
/
Antimalarials
Limits:
Animals
/
Humans
Language:
En
Journal:
Drug News Perspect
Journal subject:
FARMACOLOGIA
Year:
2010
Document type:
Article
Affiliation country:
India
Country of publication:
United States